8 results about "Contraceptive Effect" patented technology

Disclosed herein are formulation embodiments comprising levonorgestrel butanoate (“LNGB”) particles having particle sizes that facilitate administering a higher concentration of LNGB at lower volumes. The disclosed formulation embodiments exhibit long-lasting contraceptive effects and can be administered subcutaneously, which lends to their utility in acting as self-administrable contraceptive formulations that do not result in side effects associated with other contraceptive agents.

The utility model relates to a uterine cavity contraceptive device which comprises a contraceptive device body and a medicine slow release structure, and the contraceptive device body comprises a fixed section, a U-shaped section and an expandable section. The fixed section is provided with a first end and a second end, the U-shaped section is also provided with a first end and a second end, the expandable section comprises a first expandable section and a second expandable section, the two ends of the first expandable section are connected with the first end of the fixed section and the first end of the U-shaped section respectively, and the two ends of the second expandable section are connected with the second end of the U-shaped section respectively. The two ends of the second expandable section are connected with the second end of the fixed section and the second end of the U-shaped section respectively, the first end of the medicine slow-release structure is fixedly connected to the fixed section, and the medicine slow-release structure is located in a space defined by the fixed section, the U-shaped section and the expandable sections; the surfaces of the U-shaped section and the fixed section are electroplated with copper layers, the contraceptive device body can release copper ions, fertilized ovum implantation is inhibited, the contraceptive effect is achieved, the shape of the expandable section can be changed, and the contraceptive device can be conveniently placed into the uterus.

The present invention pertains to the field of oral pharmaceutical compositions and their use for providing contraception. More specifically, the present invention relates to oral chewable tablets of drospirenone, their use for providing contraception to an individual and a kit comprising daily dosage units of such oral chewable tablets.

Provided herein are thin film compositions and methods of making thin films comprising lactic acid (e.g. L-lactic acid), a water-soluble polymer, and a plasticizer. The thin films may be used for contraception and / or in preventing transmission of sexually transmitted infections.

The present disclosure relates to compounds which inhibit bromodomain testis (BRDT). In certain embodiments, the compound is a bromodomain and extra-terminal (BET) subfamily bromodomain 1 (BD1) selective compound. In certain embodiments, the compound selectively inhibits BD-1 over bromodomain 2 (BD2). The present disclosure further provides a method of inhibiting BRDT in a male subject, the method comprising administering to the male subject a therapeutically effective amount of a compound of the disclosure, whereby the male subject is provided a contraceptive effect. The present disclosure further provides a method of inhibiting BRD2, BRD3, BRD4, and / or BRDT in a subject with a cancer, inflammatory condition, infectious disease, and / or metabolic disorder in which one or more of BET proteins are regulators, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure, thereby treating, preventing, and / or ameliorating the condition, disease, and / or disorder.

The present invention relates to the field of family planning supplies and particularly to a novel contraceptive device, comprising an insertion tube, a protective cover, a liquid collection bag, a ring, and a connecting thread. The protective cover is arranged at the top end of the insertion tube. The liquid collection bag is in communication with the insertion tube. The protective cover is arranged between the liquid collection bag and the insertion tube. The ring is connected to the protective cover by means of the connecting thread. The insertion tube, the protective cover, and the ring are all flexible. The liquid collection bag is contractable. The connecting thread is retractable. The present invention has a reasonable structure, is convenient to wear, safe, and sanitary, and produces a good contraceptive effect. The protective cover and the ring are connected by means of the connecting thread instead of adopting the full-coverage design of existing common condoms, thereby greatly increasing the contact area and improving the experience.

The utility model relates to the field of gynecological appliances, in particular to a comprehensive Genimann-Luolele structure capable of releasing medicine by using a copper ring. The upper part of the fixing line can be nailed and hung in the uterine cavity; a plurality of copper rings are arranged on the fixing line in a penetrating manner, an upper bracket is arranged above a copper ring body, and a lower bracket is arranged below the copper ring body; the fixing line penetrates through the penetrating holes in the upper support and the lower support. The lower support can support medicine arranged in the copper ring, and the medicine is levonorgestrel. After the Munule and the Gini ring are combined into one and refitted, the Munule is fixed in the uterine superficial muscle layer through the Gini knot, the problems that the Munule moves downwards and falls off are perfectly solved, the treatment effect is achieved, and meanwhile the efficient and long-acting contraception effect is achieved for women with contraception requirements.

An intrauterine monitoring system is described. The system consists of an intrauterine device, designed and sized for implantation in the uterus, and a receiver. The intrauterine device measures the conditions within the uterus to generate sensor data and acts as a contraceptive method to prevent pregnancy. The receiver wirelessly receives the data generated by the intrauterine device.